Sanara MedTech Inc. (SMTI)

33.37 -0.13 (-0.39%) As of 12:26PM EDT. Market open.

Sanara MedTech Inc.

1200 Summit Avenue
Suite 414
Fort Worth, TX 76102
United States
817 529 2300
https://sanaramedtech.com

Sector(s): Healthcare
Industry: Medical Instruments & Supplies
Full-time employees: 107

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ronald T. Nixon	Executive Chairman	100k	N/A	1956
Mr. Zachary B. Fleming	Chief Executive Officer	547.6k	N/A	1975
Mr. Michael D. McNeil	CFO & Corporate Secretary	331.1k	N/A	1965
Mr. Jacob A. Waldrop	Chief Operating Officer	N/A	N/A	N/A
Mr. Bill Fitzgerald	Chief Compliance Officer	N/A	N/A	N/A
Ms. Tricia Matteson	Vice President of Marketing	N/A	N/A	N/A
Mr. Tyler Palmer	Chief Corporate Development & Strategy Officer	N/A	N/A	N/A
Dr. Christopher A. Morrison FACHM, FAPWCA, FCCWS, M.D.	President of Telehealth Services	156k	N/A	1970
Dr. Rebecca Erin Mcmahon	President of Research & Development	N/A	N/A	1985
Mr. Seth Yon	President of Commercial	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Corporate governance

Sanara MedTech Inc.’s ISS governance QualityScore as of 1 May 2024 is 6. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.